Skip to main content

JAK/TYK2

      JAK Safety Update
      Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.
      JAK inhibitors have taken a beating over the last three years. The excitement and potential has been tempered by mounting cardiovascular safety concerns, but specifically in at-risk patients, compared to TNF inhibitors. So it is an intriguing idea to pair JAK inhibitors with something that might have a cardioprotective effect. It is therefore worth excitement that we have a therapeutic option to follow which does just that. At EULAR 2025, we
      Seronegative Arthritis Breakthroughs

      Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high

      Dr. John Cush RheumNow

      2 weeks 5 days ago
      Seronegative Arthritis Breakthroughs Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel https://t.co/7nmOWw11lb
      Advances in Lupus
      Deucravacitinib in PsA
      Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following.
      RA Care Should be Guided by Need—Not Age

      Dr. Jiha Lee reports on abstract POS0627, "Examination of Clinical Outcomes

      Dr. John Cush RheumNow

      2 weeks 6 days ago
      RA Care Should be Guided by Need—Not Age Dr. Jiha Lee reports on abstract POS0627, "Examination of Clinical Outcomes by Treatment Duration of Biologics and JAK inhibitors in Nonagenarian Rheumatoid Arthritis," at EULAR 2025 in Barcelona, Spain. https://t.co/zKHXZSVLJy https://t.co/w6CkRy2yIA
      EULAR Daily Recap: Day 4
      At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities, and patient factors that shape each clinical decision.
      ×